China SXT Pharmaceuticals, Inc. cash flow statement SXTC

Annual Quarterly

In fiscal 2026, which ended Mar 31, 2026, China SXT Pharmaceuticals, Inc. used $4.0 million of cash from operations, down 71.3% from the year before.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line	FY 2026 Mar 31, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Mar 31, 2022	FY 2021 Mar 31, 2021	FY 2020 Mar 31, 2020	FY 2019 Mar 31, 2019
Operating
Depreciation and amortization	0 -10.5%	0 -59.5%	0 -18.8%	0 -21.8%	0 -7.4%	0 +4.1%	0 +90.7%	0
Stock-based compensation	5 +1406.9%	—	0	—	—	—	—	—
Operating cash flow	-4 -71.3%	-2 -21.6%	-2 -2287.5%	-0 -130.1%	0 +120.4%	-1 -240.9%	1 +290.6%	0
Investing
Capital expenditures	—	0	—	—	—	—	0 -75.6%	1
Investing cash flow	-1 -2069.5%	0 +140.4%	0 +314.8%	-0 +73.8%	-0 +99.2%	-6 -5.6%	-5 -801.0%	-1
Financing
Debt repaid	—	—	—	—	—	—	1 +2676.2%	0
Short-term debt issued	—	—	—	—	—	—	—	0
Financing cash flow	14 +71.8%	8 +420.0%	-3 -189.2%	3 +84.4%	2 -87.1%	12 +310.3%	3 -66.6%	9
Change in cash
Effect of exchange rate	—	—	—	—	—	1 +268.1%	-0 -1160.8%	-0
Net change in cash	10 +66.0%	6 +214.4%	-5 -394.1%	2 -18.6%	2	—	—	—
Free cash flow	—	-2	—	—	—	—	1 +370.8%	-0
Per share
Free cash flow per share	—	-247.38	—	—	—	—	—	-0.01
Ratios
Free cash flow margin	—	-134.84%	—	—	—	—	15.56%	-4.23%
Capital expenditures to revenue	—	0.12%	—	—	—	—	2.53%	7.64%
Stock-based compensation to revenue	466.21%	—	18.26%	—	—	—	—	—
Cash conversion	—	—	—	—	—	—	—	0.16x

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: SXTC (Nasdaq)
Fiscal year ends: March 31
Incorporated in: Virgin Islands, British
Headquarters: Taizhou
SEC filer status: Non-accelerated filer
SEC CIK: 1723980

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.